This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Celgene Revlimid Growth Plans Stopped Dead

SUMMIT, NJ ( TheStreet) --European regulators have rejected Celgene's (CELG) request for an expanded approval of its multiple myeloma drug Revlimid to treat newly diagnosed patients, a stunning setback that slams the brakes on the company's growth.

Celgene shares were down $8, or 12%, to $59.15 in early Thursday trading.

Investors were widely expecting Celgene to announce expanded European regulatory approval of Revlimid as a treatment for newly diagnosed multiple myeloma patients and as maintenance therapy following stem cell transplant. But in a surprise move, the company disclosed Thursday that it was withdrawing the Revlimid submission, and at the request of European regulators, will re-submit at a later date with more mature data.

Onyx Pharmaceuticals (ONXX), another multiple myeloma drug company, is faring much better after an FDA advisory panel voted unanimously to recommend the approval of Kyprolis for patients with late-stage disease. Onyx shares were up 36% to $60.94 in early trading.

Revlimid is Celgene's largest and most important cancer drug, already approved in Europe and the U.S. for more advanced, or late-stage multiple myeloma therapy. Revlimid sales in 2011 totaled $3.2 billion or 66% of the Celgene's total revenue of $4.8 billion last year. Celgene management and investors have cited the expansion of Revlimid's use into newly diagnosed patients as the company's most crucial catalyst and growth driver.

Now, however, that growth driver has hit a wall. The last time a major biotech company suffered a similar, devastating setback was when Biogen Idec (BIIB) was forced to pull its multiple sclerosis drug Tysabri from the market.

Celgene reaffirmed its 2012 earnings forecast but it's lagging profits in 2013 and beyond that will be worrying investors Thursday. Currently, Celgene is expected to earn $5.61 per share on total revenue of $6.17 billion in 2013. With Revlimid's expansion on hold, Celgene will be hard pressed to produce 17% earnings growth next year.

Further adding to Celgene's woes, the company also said it was "re-evaluating" a submission to the U.S. Food and Drug Administration to similarly expand Revlimid's use here. The company now anticipated submitting an FDA application in 2013.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7870 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs